A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 900
- Registration Number
- NCT06551519
- Locations
- 🇩🇪
Novartis Investigative Site, Stuttgart, Germany
A Study to Evaluate the Impact of Long-term Digital Education vs Standard of Care on LDL-C Levels in Post Myocardial Infarction Patients
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT06548555
- Locations
- 🇨🇿
Novartis Investigative Site, Praha, Czechia
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 138
- Registration Number
- NCT06546670
- Locations
- 🇺🇸
Quotient Sciences Sea View, Miami, Florida, United States
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 106
- Registration Number
- NCT06531499
- Locations
- 🇺🇸
Nebraska Cancer Specialists, Omaha, Nebraska, United States
🇬🇧Novartis Investigative Site, Sutton, Surrey, United Kingdom
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 146
- Registration Number
- NCT06517758
- Locations
- 🇺🇸
Fullerton Neuro and Headache Ctr, Fullerton, California, United States
🇺🇸SC3 Research Pasadena, Pasadena, California, United States
🇺🇸Superior Associates in Research LLC, Hialeah, Florida, United States
Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT06517732
- Locations
- 🇷🇺
Novartis Investigative Site, Tula, Russian Federation
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT06517719
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Post Marketing Study on Pluvicto in Korea
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 278
- Registration Number
- NCT06514521
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT06514534
LATAM LOWERS LDL-C
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 520
- Registration Number
- NCT06501443
© Copyright 2024. All Rights Reserved by MedPath